Beyond Hormones: How Your X And Y Chromosomes Secretly Shape Your Disease Risk

Beyond Hormones: The Overlooked Genetic Drivers of Disease

For decades, medical science has largely attributed the health disparities between men and women to the fluctuating influence of sex hormones like estrogen and testosterone. However, a comprehensive new review published in Science suggests that our understanding of biological sex has been incomplete. The study reveals that the X and Y chromosomes are not merely markers of sex, but are active, primary drivers of how our cells age, function, and defend against life-threatening illnesses.

The research, co-led by physician-scientist Dan Theodorescu of the University of Arizona Cancer Center and Dena B. Dubal of the University of California, San Francisco, synthesizes evidence from human studies, mouse models, and advanced genomic sequencing. The findings challenge the hormone-centric view of medicine, demonstrating that genetic instructions encoded directly on these chromosomes significantly influence susceptibility to cancer, cardiovascular disease, neurological decline, and immune system dysfunction.

“X and Y chromosomes are often thought of as simple determinants for biological sex, but their role in human health is much larger,” says Theodorescu, who also serves as chair and director of the University of Arizona Cancer Center. “Our review shows that these chromosomes carry genetic instructions that shape how our cells age and how our bodies defend against major diseases throughout our lives.”

The Genetic Mechanics of Aging and Illness

The review details complex cellular processes that affect health throughout the human lifespan. In women, early development involves the silencing of one X chromosome; however, this process is not always absolute. Some genes remain active, and others can reactivate over time, potentially providing female cells with unique gene dosages. Research in mouse models indicates that the origin of these chromosomes—whether inherited from the mother or father—can have distinct outcomes, with evidence suggesting that a reliance on the maternal X chromosome may be linked to accelerated memory decline and brain aging.

Equally critical is the phenomenon of sex chromosome loss as people age. In women, the loss of an X chromosome is associated with an increased risk of leukemia. In men, the loss of the Y chromosome—most frequently observed in blood cells—is increasingly recognized as a clinical marker for a spectrum of age-related conditions, including heart disease, severe infections, Alzheimer’s disease, and various cancers.

Transforming Clinical Care Through Precision Medicine

The implications for clinical practice are profound. By moving beyond a one-size-fits-all model, researchers hope to usher in a new era of personalized diagnostics and treatments that account for an individual’s unique chromosomal profile.

Theodorescu’s own work has provided a compelling look at how this plays out in oncology. His laboratory previously discovered that when tumors lose the Y chromosome, they develop a sophisticated mechanism to evade the immune system. Interestingly, while this makes the tumors more aggressive, it may also render them more susceptible to specific immunotherapies. Identifying the loss of the Y chromosome in otherwise healthy-looking tissue could serve as an early warning system, identifying patients at high risk for cancer development.

“In cancer, for example, our laboratory has found that tumors that lose the Y chromosome can evade the immune system, yet may respond better to immunotherapy,” says Theodorescu. “Understanding this biology could help us tailor treatment.”

A Call for Sex-Aware Clinical Trials

The authors argue that integrating this chromosomal data into clinical trials is essential for medical advancement. Current trial designs often fail to account for the fundamental genetic differences driven by sex chromosomes, which may obscure the efficacy of new drugs or hide critical safety signals.

The review, which was informed by discussions at the 2025 National Institute on Aging Workshop on sex differences, highlights a path forward: by designing trials that are inherently “sex-aware,” researchers can transform these biological differences into actionable insights. This shift could lead to more effective, targeted therapies that move away from generalized standards of care and toward precision medicine tailored to the patient’s complete genetic identity.

The research team, which included contributors from the Schoen Adams Research Institute of Harvard Medical School and the Oklahoma Medical Research Foundation, received support from the National Institutes of Health and the US Department of Veterans Affairs. As scientists continue to unravel the influence of the X and Y chromosomes, the focus remains on ensuring that these discoveries translate into improved diagnostic tools and patient outcomes.